earnings
confidence high
sentiment positive
materiality 0.85
ANI Pharma Q2 record revenues $211.4M, EPS $0.36; lifts FY guidance
ANI PHARMACEUTICALS INC
2025-Q2 EPS
reported $1.05
vs consensus $1.45
▼ miss
(-27.5%)
- Q2 net revenue $211.4M (+53.1% YoY); GAAP EPS $0.36 vs ($0.14); record adjusted EBITDA $54.1M (+62.8%).
- Rare Disease rev $104.0M (Cortrophin Gel $81.6M, +66%; ILUVIEN/YUTIQ $22.3M).
- Generics rev $90.3M (+22.1%); driven by new launches including first-to-market prucalopride.
- Raised FY2025 guidance: rev $818M–$843M; adj EBITDA $213M–$223M; adj EPS $6.98–$7.35.
- Cash & equivalents $217.8M; year-to-date CFO $110.8M.